Nasdaq Fdmt News Today

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have been given an average rating of “Buy” by the ten research firms that are presently covering the firm, MarketBeat.com reports. Ten investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued ratings on […]

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) has received an average recommendation of “Buy” from the ten analysts that are covering the company, MarketBeat reports. Ten investment analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have covered the stock in the last year […]

Bfsg LLC acquired a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 1,500 shares of the company’s stock, valued at approximately $30,000. A number of other hedge funds have also recently modified their holdings of FDMT. RA Capital Management L.P. boosted […]

Bfsg LLC acquired a new stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,500 shares of the company’s stock, valued at approximately $30,000. A number of other institutional investors and hedge funds […]

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) were down 2.3% during trading on Wednesday . The company traded as low as $26.13 and last traded at $26.13. Approximately 43,923 shares were traded during mid-day trading, a decline of 96% from the average daily volume of 1,080,685 shares. The stock had previously […]

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) dropped 2.3% on Wednesday . The company traded as low as $26.13 and last traded at $26.13. Approximately 43,923 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 1,080,685 shares. The stock had previously closed at $26.75. Wall Street […]

4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) had its price target boosted by Royal Bank of Canada from $35.00 to $40.00 in a research report released on Monday morning, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the stock. A number of other equities research analysts have also issued reports on […]

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) insider Scott Bizily sold 8,153 shares of 4D Molecular Therapeutics stock in a transaction on Monday, April 1st. The stock was sold at an average price of $31.78, for a total value of $259,102.34. Following the transaction, the insider now directly owns 1,737 shares of the […]

4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) had its price objective hoisted by Jefferies Financial Group from $30.00 to $58.00 in a research report report published on Monday morning, Benzinga reports. They currently have a buy rating on the stock. FDMT has been the topic of a number of other research reports. The Goldman Sachs […]

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) shares reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $35.72 and last traded at $35.58, with a volume of 265016 shares trading hands. The stock had previously closed at $34.05. Analysts Set New Price Targets A number […]